Stock List

Search by Ticker



Incyte Corporation (NASDAQ:INCY)
Stock Analysis

▲ 1.33%1.24

Stock Analysis

The following stock analysis is based on 7.5 years of data (i.e. since Feb 08, 2013). All the stock history has been downloaded.

Stock Exchange

Incyte Corporation trades on the NasdaqGS exchange in USD dollars.


It is in the sector.

Current Status of Incyte Corporation

It is currently trading at $94.22 ($92.98 the previous day).


The next reporting date is in 82 days (2020 11 03).

CNN estimates profits for the upcoming quarter will be $0.51 per share ($620.3M). The current Canada / US exchange rate is 1.32234.

Over the past 12 months, $205 worth of shares have been purchased and $52422549 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is -2.8% per year assuming steady exponential growth. The actual 5 year average is 2.28. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year84.52275157894712+ Above Average
2 year75.44504-15- Below Average
3 year88.743907563025-23.8- Below Average
4 year116.5082786885228.3+ Above Average
5 year90.789695817499.9+ Above Average
Incyte Corporation is projected by analysts to get to $100.50 within the next 12 months (6.7%), but preticted targets range from as high as $132.00 (40.1%) and as low as $87(-7.7%).


The worst drop it has had in recent years is -61.7%. It has a shape to the stock curve, which means

Stock shape test


Tradingview BuySell Widget

Yahoo News Feed

NIH to test remdesivir with Merck KGaAand's interferon therapy as a COVID-19 treatment

Fri, 07 Aug 2020 13:11:00 The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.and's remdesivir with Merck KGaAand's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 ...... Read Full Article

Incyte Earnings Soar 65%, Easily Beating Views

Tue, 04 Aug 2020 20:11:01 Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance. INCY stock was not yet active early Tuesday.... Read Full Article

Incyte Corp (INCY) Q2 2020 Earnings Call Transcript

Tue, 04 Aug 2020 19:00:38 INCY earnings call for the period ending June 30, 2020.... Read Full Article

Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi

Tue, 04 Aug 2020 14:10:02 Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.... Read Full Article

Dow Jones Today Dips, Nasdaq Fights To Extend Streak; Take-Two, SolarEdge, AMD Rocket

Tue, 04 Aug 2020 13:58:09 Take-Two, Inphi and Incyte rallied Tuesday, but stock futures dipped as the Dow Jones looked toward Disneyand's after-hours report.... Read Full Article

Incyte (INCY) Q2 Earnings and Revenues Beat Estimates

Tue, 04 Aug 2020 12:45:12 Incyte (INCY) delivered earnings and revenue surprises of 61.04% and 15.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Tue, 04 Aug 2020 11:00:00 Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs... Read Full Article

Dow Jones Today, Stocks Rise As Microsoft Courts TikTok; Varian Soars On Siemens Deal; Incyte, Co-Diagnostics FDA News

Mon, 03 Aug 2020 13:55:40 Incyte paced the Nasdaq, Microsoft led the Dow Jones, and stock futures rose as global markets rallied on strong manufacturing data.... Read Full Article

Is a Surprise Coming for Incyte (INCY) This Earnings Season?

Mon, 03 Aug 2020 12:38:12 Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.... Read Full Article

Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab

Mon, 03 Aug 2020 06:08:45 Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified.This includes DLBCL arising from ...... Read Full Article

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Fri, 31 Jul 2020 23:51:00 FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory DLBCL... Read Full Article

10 Biggest Biotechnology Companies

Thu, 30 Jul 2020 23:32:40 With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.... Read Full Article

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Tue, 28 Jul 2020 16:33:04 Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article

Is a Beat in the Cards for Incyteand's (INCY) Q2 Earnings?

Tue, 28 Jul 2020 15:40:03 Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.... Read Full Article

Does Incyteand's (NASDAQ:INCY) CEO Salary Compare Well With Industry Peers?

Mon, 27 Jul 2020 17:54:31 Hervé Hoppenot became the CEO of Incyte Corporation (NASDAQ:INCY) in 2014, and we think itand's a good time to look at...... Read Full Article

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

Fri, 24 Jul 2020 18:06:35 These five high yield drug stocks pay dividends with attractive yields, and also are undervalued. And as a result, these stocks offer good upside potential to investors. As a group, they are cheap. Yet, they have solid earnings that cover ...... Read Full Article

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

Thu, 23 Jul 2020 11:15:00 Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoint... Read Full Article

Incyte Could Rise Another 15% From Here

Mon, 20 Jul 2020 16:53:00 Incyte Inc. is in a cutting-edge industry and its shares are poised for an upside breakout. Letand's check out the charts for a technical strategy that makes sense. In the daily bar chart of INCY, below, we can see some ...... Read Full Article

Incyte to Report Second Quarter Financial Results

Thu, 16 Jul 2020 12:00:00 Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 4, 2020.... Read Full Article

Steven Cohen Homes in on Otonomy

Wed, 15 Jul 2020 17:15:54 Guru ups bet in biotech focused on ear-related disorders Continue reading...... Read Full Article